



## COMPANY OVERVIEW

Synthetic Biologics, Inc. is a late-stage clinical company developing therapeutics that preserve the microbiome to protect and restore the health of patients. The Company's lead candidates poised for Phase 3 development are: (1) SYN-004 (ribaxamase) which is designed to protect the gut microbiome from the effects of certain commonly used intravenous (IV) beta-lactam antibiotics for the prevention of *C. difficile* infection (CDI), overgrowth of pathogenic organisms and the emergence of antimicrobial resistance (AMR), and (2) SYN-010 which is intended to reduce the impact of methane producing organisms in the gut microbiome to treat an underlying cause of irritable bowel syndrome with constipation (IBS-C). The Company's preclinical pursuits include an oral formulation of the enzyme intestinal alkaline phosphatase (IAP) to treat both local GI and systemic diseases as well as monoclonal antibody therapies for the prevention and treatment of pertussis, and novel discovery stage biotherapeutics for the treatment of phenylketonuria (PKU).

## RECENT NEWS

### Synthetic Biologics Announces Acceptance of Compliance Plan by NYSE American

May 22 2018, 7:00 AM EDT

## STOCK OVERVIEW

Symbol	SYN
Exchange	NYSE American
Market Cap	27.26m
Last Price	\$0.212
52-Week Range	\$0.19 - \$1.05

## INVESTOR RELATIONS

Synthetic Biologics, Inc.  
Investor Relations Department  
T: (301) 417-4364  
[info@syntheticbiologics.com](mailto:info@syntheticbiologics.com)

## MANAGEMENT TEAM

### Steven Shallcross

Interim CEO, Chief Financial Officer,  
Treasurer and Secretary

### Joseph Sliman, MD, MPH

Chief Medical Officer

### Michael Kaleko, MD, PhD

Senior Vice President, Research &  
Development

### Raymond D. Stapleton, Jr., PhD

Senior Vice President, Manufacturing

### Deb Mathews, PharmD

Vice President, Medical Affairs

## SYNTHETIC BIOLOGICS, INC.

9605 Medical Center Drive  
Suite 270  
Rockville, MD 20850  
US  
T: (301) 417-4364  
<https://www.syntheticbiologics.com>

## DISCLAIMER

Except for the historical information contained herein, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in the Company's industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on Form 10-K and its quarterly reports on Form 10-Q. The Company does not undertake any obligation to update forward-looking statements.